FDA Provides 510(k) Clearance for Philips' CT Verida System</h1> <article> <h1>FDA Provides 510(k) Clearance for Philips' CT Verida System</h1> <p>tim.hodson — Mon, 20 Apr 2026 22:20:35 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Philips Spectral CT Verida System<br /> (Photo: Royal Philips)</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 04/20/2026 - 17:20</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 16, 2026 — The U.S. Food and Drug Administration has granted 510(k) clearance to <a href="https://www.philips.com/a-w/about/news-and-insights.html" target="_blank">Royal Philips</a> for its <a href="https://www.philips.com/a-w/about/news/archive/standard/news/press/2025/philips-launches-verida-worlds-first-detector-based-spectral-ct-powered-by-breakthrough-ai-to-advance-diagnostic-precision.html" target="_blank">Philips Spectral CT Verida</a> system, bringing its next-generation, AI-powered spectral CT innovation to the United States.</p> <p>Verida incorporates Spectral Precise Image, with a third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction, along with an AI-based deep learning reconstruction engine, designed to reduce noise and enhance image quality across CT applications<sup>1</sup>. Clinicians are able to customize optimal image de-noising according to their preferences.</p> <p>“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets,” said Dan Xu, Business Leader of CT at Philips. “By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”</p> <p>Built on Philips’ industry-leading detector-based spectral CT technology, Verida enables always-on spectral imaging without requiring separate scans or workflow changes. It includes system and software enhancements designed to support clinical workflow, including improvements to the spectral result generation pipeline and updated computing infrastructure to support performance and usability. Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than previously, enabling up to 270 exams every day<sup>2</sup>.</p> <p>By capturing both high- and low-energy data in a single acquisition, clinicians can access conventional and spectral results simultaneously, supporting enhanced tissue characterization and material differentiation. This approach eliminates the need for pre-selection or repeat scans, enabling first-time-right imaging and deeper clinical insight across a broad range of applications<sup>3</sup>.</p> <p>Verida is a computed tomography X-ray system intended for diagnostic imaging in radiology, interventional radiology, and cardiology, and in oncology as part of treatment preparation and radiation therapy planning. It is indicated for head, whole body, cardiac, and vascular CT applications in patients of all ages<sup>1</sup>. The system is also intended to be used for low dose CT lung cancer screening when performed within established screening protocols<sup>4</sup>. Extended field-of-view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation use only<sup>3</sup>.</p> <p>For more information about the Philips Spectral CT Verida system, visit <a href="https://www.philips.co.uk/healthcare/product/728345/verida-spectral-detector-ct-scanner" target="_blank">the Philips website.</a> </p> <p> </p> <p><em>* Data on file</em></p> <ol><li>Spectral Precise Image is an AI-based reconstruction feature with supplemental data for clinical interpretation and does not replace professional clinical judgement. SPI has been clinically evaluated in adults (≥22 years); pediatric use has not been clinically validated.</li> <li>Spectral CT Verida Premium up to 270 (4 CIRS config) exams a day (16 hours dual shift working day) meeting the needs of radiology departments with extended work hours and very high patient throughput.</li> <li>See Instructions for Use for complete indications, limitations, and feature-specific restrictions.</li> <li>Please refer to clinical literature, including the results of the National Lung Screening Trial (NEngl. J Med 2011; 365:395-409) and subsequent literature, for further information.</li> </ol></div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/fda-provides-510k-clearance-philips-ct-verida-system" data-a2a-title="FDA Provides 510(k) Clearance for Philips' CT Verida System"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Ffda-provides-510k-clearance-philips-ct-verida-system&title=FDA%20Provides%20510%28k%29%20Clearance%20for%20Philips%27%20CT%20Verida%C2%A0System"></a></span> </article> <article> <h1>New Study Shows Strong Outcomes for Transcatheter Tricuspid Valve Replacement</h1> <p>tim.hodson — Mon, 20 Apr 2026 19:44:38 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Photo: Cedars-Sinai</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 04/20/2026 - 14:44</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that transcatheter tricuspid valve replacement, or TTVR, delivered strong early results in real-world practice. Patients treated with TTVR experienced near elimination of tricuspid regurgitation, low rates of stroke, and meaningful improvements in symptoms and quality of life within 30 days.</p> <p>The study, “Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry,” published in the <a href="https://jamanetwork.com/journals/jama/article-abstract/2847572?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2026.3446"><i>Journal of the American Medical Association.</i></a></p> <p>“These findings show that transcatheter tricuspid valve replacement is translating well from the clinical trial setting into routine practice across the United States,” said <a href="https://researchers.cedars-sinai.edu/Raj.Makkar?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Aminimally-invasive-procedure-for-aortic-valve-disease-has-similar-outcomes-as-surgery-study-reports">Raj Makkar, MD</a>, vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai, the Karsh Distinguished Chair in Interventional Cardiology in the Smidt Heart Institute, and corresponding author of the study. “In a large, older and medically complex patient population, we saw very high procedural success, near-complete elimination of tricuspid regurgitation, and rapid improvement in how patients feel and function.”</p> <p><a href="https://www.cedars-sinai.org/newsroom/new-options-for-people-with-tricuspid-valve-disease/">Tricuspid regurgitation </a>occurs when the tricuspid valve does not close properly, allowing blood to flow backward in the heart. The condition is common in older adults and can lead to worsening heart failure symptoms, repeated hospitalization and increased risk of death.</p> <p>Historically, open-heart surgery was often the only treatment option for this condition, but many older patients were not candidates because of age or other medical problems. Today, transcatheter tricuspid valve replacement offers a less invasive alternative in which doctors replace the damaged valve using a catheter, or tube, threaded through a blood vessel.</p> <p>Researchers analyzed 1,034 attempted TTVR procedures performed between February 2024 and March 2025 at 82 medical centers across the U.S. The average patient age was 77.</p> <p>The analysis found that more than 98% of patients had the valves successfully implanted. At 30 days post-procedure, more than 97% of patients had their condition improve to mild or minimal tricuspid regurgitation, and patients reported substantial improvement in symptoms, physical and social function, and quality of life.</p> <p>Study authors note that early real-world outcomes <a href="https://www.cedars-sinai.org/newsroom/smidt-heart-institute-physicians-advance-transcatheter-tricuspid-valve-replacement/">were consistent </a>with results from the TRISCEND II randomized trial of TTVR. Patients in this new study, however, experienced lower incidence of bleeding and heart block requiring electronic pacemaker implantation than patients participating in TRISCEND II. The current study also found that outcomes were generally consistent in patients with and without preexisting cardiac implantable electronic devices such as pacemakers, an important finding because these devices are common in patients with severe tricuspid valve disease.</p> <p>“For patients with severe tricuspid regurgitation, treatment options have historically been limited, especially when surgery carries high risk,” said <a href="https://researchers.cedars-sinai.edu/Aakriti.Gupta?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-heart-experts-available-for-interviews-at-aha25&adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1774047971&previousPageName=cs-org%253Acedars-sinai%253Aother">Aakriti Gupta, MD</a>, assistant professor of Cardiology and study author. “What is especially encouraging here is that in real-world care, not just in a randomized trial, patients experienced meaningful improvement in symptoms and quality of life within only 30 days.”</p> <p>Investigators said the results support the growing role of TTVR as a treatment option for patients with severe tricuspid regurgitation and highlight the importance of continued follow-up to understand longer-term outcomes.</p> <p><a href="https://researchers.cedars-sinai.edu/Moody.Makar?adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1774048903&previousPageName=cs-org%253Acedars-sinai%253Aother">Moody Makar, MD</a>, associate professor of Anesthesiology at Cedars-Sinai, is also an author of the study.</p> <p> </p> <p><i>Additional authors include Brian P. O’Neill, MD; Christina Lalani, MD; Rahul Sharma, MBBS; Pradeep Yadev, MD; Tiberio M. Frisoli, MD; Vinod Thourani, MD; Mackram F. Eleid, MD; James Lee, MD; Vasilis C. Babaliaros, MD; Christiane Haeffele, MD, MPH; Tanvir J. Bajwa, MD; Peter Flueckiger, MD; Robert J. Cubeddu, MD; Laura J. Davidson, MD; Ratnasari Padang, MBBS, PhD; Pedro Villablanca Spinetto, MD; Suhail Allaqaband, MD; Akhil Narang, MD; Mathew Williams, MD; Patrick Gleason, MD; Gilbert H.L. Tang, MD; Sahil Khera, MD; John P. Vavalle, MD; Isida Byku, MD; Jeremiah P. Depta, MD; Santiago Garcia, MD; Samir Kapadia, MD; Alan Zajarias, MD; Jake M. Chanin, MD; Susheel K. Kodali, MD; Howard C. Herrmann, MD; M. Andrew Morse, MD; George Petrossian, MD; Joseph A. Sivak, MD; Rebecca T. Hahn, MD; Yang Song, PhD; Martin B. Leon, MD; Robert W. Yeh, MD, MSc; Charles J. Davidson, MD.</i></p> <p> </p> <p><i>The study was funded by Edwards Lifesciences.</i></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/new-study-shows-strong-outcomes-transcatheter-tricuspid-valve-replacement" data-a2a-title="New Study Shows Strong Outcomes for Transcatheter Tricuspid Valve Replacement"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fnew-study-shows-strong-outcomes-transcatheter-tricuspid-valve-replacement&title=New%20Study%20Shows%20Strong%20Outcomes%20for%20Transcatheter%20Tricuspid%20Valve%20Replacement"></a></span> </article> <article> <h1>FDA Clears Non-invasive Cardiac Mapping Platform</h1> <p>tim.hodson — Mon, 20 Apr 2026 19:43:00 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 04/20/2026 - 14:43</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 17, 2026 — Corify Care has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS System, an imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac electrical activity in real-time.</p> <p>This marks a fundamental shift in electrophysiology. By combining high-resolution 3D anatomical models with real-time electrical activity, the ACORYS System introduces true 4D cardiac mapping. This instant, whole-heart functional insight enables faster, safer and more predictable ablation procedures</p> <p>Designed to complement modern EP workflows, ACORYS empowers physicians with real-time, panoramic mapping of complex arrhythmia mechanisms. This approach allows clinical teams to gain immediate functional insight without the need for pre-procedural imaging or the induction of unstable arrhythmias.</p> <p>“FDA clearance of ACORYS is a defining moment — not just for Corify, but for the future of electrophysiology,” said Andreu Climent, PhD, CEO of Corify Care. “For decades, EP has been limited by incomplete and time-intensive contact based mapping. ACORYS changes the paradigm — by delivering immediate pre-procedural and inter-procedural, global insight that allows physicians to understand complexity, define targets, and act with confidence from the very first beat.”</p> <p>ACORYS provides clinicians with:</p> <ul><li> <p>Single-beat, global cardiac mapping across all four chambers</p> </li> <li> <p>Imageless workflow — no CT or MRI required</p> </li> <li> <p>Pre-procedural, intra-procedural, and inter-procedural to assess arrhythmia complexity in real -time</p> </li> <li> <p>Non-invasive functional mapping that complements standard catheter workflows</p> </li> <li> <p>Rapid identification of arrhythmogenic substrate, including VT, complex atrial tachyarrhythmias or cardiac desynchronization</p> </li> </ul><p>Validated in more than 2,500 patients across leading electrophysiology centers in Europe, Corify Care will present new clinical data alongside several scientific studies, at the Heart Rhythm Society (HRS) 2026 conference in Chicago. These studies along with significant prior clinical validation has demonstrated strong performance across both atrial and ventricular applications including:</p> <ul><li> <p>High accuracy in identifying arrhythmia mechanism, chamber of origin, and ablation targets</p> </li> <li> <p>Ability to localize ventricular tachycardia substrate in sinus rhythm, reducing the need for inducing unstable arrhythmias</p> </li> <li> <p>Precise mapping of atrial activation patterns</p> </li> </ul><p>“ACORYS gives us something we’ve never had before—a complete understanding of the arrhythmia before we even start ablating,” said Felipe Atienza, MD, CMO and Co-Founder of Corify Care. “This has the potential to dramatically change how we approach complex cases, particularly in VT and Atrial Tachyarrhythmias.”</p> <p>Following FDA clearance, Corify Care will initiate a phased U.S. commercial rollout, partnering with leading electrophysiology centers to drive adoption of its next-generation mapping platform.</p> <p> More information is available at <a href="http://www.corify.es">www.corify.es</a></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/fda-clears-non-invasive-cardiac-mapping-platform" data-a2a-title="FDA Clears Non-invasive Cardiac Mapping Platform"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Ffda-clears-non-invasive-cardiac-mapping-platform&title=FDA%20Clears%20Non-invasive%20Cardiac%20Mapping%20Platform"></a></span> </article> <article> <h1>Nicklaus Children's Hospital's Heart Institute Performs Florida's First Partial Heart Transplant</h1> <p>tim.hodson — Mon, 20 Apr 2026 19:32:10 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 04/20/2026 - 14:32</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 16, 2026 — The cardiovascular surgery team at <a href="https://www.nicklauschildrens.org/home">Nicklaus Children's Hospital's Heart Institute</a> has successfully performed the first partial heart transplant in the state of Florida on a 11-year-old patient. With an implanted "living valve," the procedure is designed to prevent the need for future open-heart surgeries because the valve will grow with the child as they age.</p> <p>In this major surgical innovation, the living valve of a donor's heart is implanted into a patient, which allows the living valve to grow with the child. This is an alternative to prosthetic valves that do not have the capability to grow as the patient matures. Traditionally used animal-derived and mechanical prosthetic valves deteriorate over time or require the daily use of blood thinners. These non-living valves also need to be replaced over time, leading to additional open-heart surgeries, and are associated with a decreased survival rate after implantation.</p> <figure role="group" class="align-left"><br /><figcaption>Greyson, his family and his care team celebrate his discharge from the hospital. (Photo: Nicklaus Children's Hospital's Heart Institute)</figcaption></figure><p>This breakthrough procedure was led by Chief of Cardiovascular Surgery, Co-director of the Nicklaus Children's Heart Institute as well as Professor and Researcher at the FIU Herbert Wertheim College of Medicine, Dr. David Kalfa. The partial heart transplant highlights Dr. Kalfa as a pioneer in the development and clinical application of living heart valve implants for children.</p> <p>"Partial heart transplants are redefining what's possible in pediatric heart surgery. By transplanting a living valve, we are not just repairing a defect. We are restoring function in a way that allows the heart to grow naturally," said Dr. Kalfa. "Our goal is to move beyond temporary solutions like prosthetic materials and provide children with long-lasting, life-changing outcomes."</p> <p>Greyson, the 11-year-old patient who underwent the procedure, had two additional heart surgeries as a baby prior to coming to Nicklaus Children's. His family is hopeful that he will not require another open-heart surgery in the future thanks to this innovative procedure.</p> <p>"Going in for a second opinion is what brought me to Nicklaus Children's and Dr. Kalfa with his years of expertise and research in the field, and I am so grateful for that," says, Piera Archila, Greyson's mother. "Greyson underwent open-heart surgery in New York and has since been to a few other children's hospitals in Florida and outside the state in search for answers for his condition. Nicklaus Children's offered something unique in that Greyson can now grow up without needing another open-heart surgery."</p> <p>Congenital heart defects are the most common birth defects, affecting nearly 1% of newborns in the U.S., or about 40,000 infants. Of those infants born with CHD, half will need an operation to fix or replace a valve.</p> <p>Dr. Kalfa's work is supported in part by grants from the National Institutes of Health in collaboration with FIU, advancing research and clinical innovation in partial heart transplantation and pediatric valve preservation techniques.</p> <p>Nicklaus Children's Hospital is ranked among the nation's "Best Children's Hospitals" by U.S. News & World Report, with seven specialty ranked programs, including Nicklaus Children's Heart Institute ranked the #1 heart program for children in South Florida.</p> <p>For more information, please visit <a href="https://www.nicklauschildrens.org/home">www.nicklauschildrens.org</a>.</p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/nicklaus-childrens-hospitals-heart-institute-performs-floridas-first-partial-heart" data-a2a-title="Nicklaus Children's Hospital's Heart Institute Performs Florida's First Partial Heart Transplant"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fnicklaus-childrens-hospitals-heart-institute-performs-floridas-first-partial-heart&title=Nicklaus%20Children%27s%20Hospital%27s%20Heart%20Institute%20Performs%20Florida%27s%20First%20Partial%20Heart%20Transplant"></a></span> </article> <article> <h1>Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ</h1> <p>tim.hodson — Wed, 15 Apr 2026 20:14:46 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Wed, 04/15/2026 - 15:14</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 15, 2026 – <a href="https://elucid.com/">Elucid</a> has announced the commercial availability of a new Lesion Inspection Tool for coronary and carotid plaque analysis in its novel <a href="https://elucid.com/#plaque">Plaque-IQ</a> software suite. The tool provides physicians the ability to interrogate lesion-specific composition and plaque burden across any vessel, which can help the physician better understand the patient risk profile to enhance clinical decision-making.</p> <p>“The Lesion Inspection Tool provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics,” said Jimmy Kerrigan, MD, an interventional cardiologist with Ascension Saint Thomas Heart. “Because cardiovascular events like heart attacks occur at the lesion level, having the ability to characterize individual lesions enhances my understanding of a patient’s disease process and supports more informed clinical decision-making.”</p> <p>Plaque-IQ’s Lesion Inspection Tool allows users to interrogate any lesion or region, and access quantitative results displayed for the specific segment. By providing precise quantification of plaque types at the lesion level, the tool allows physicians to quantify high-risk features like lipid-rich necrotic core (LRNC). This objective and actionable data supports proactive, individualized treatment strategies. </p> <p>Elucid’s Plaque-IQ is trained and validated against objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology (CT-VH), Plaque-IQ noninvasively quantifies and classifies coronary and carotid plaque and its components – including LRNC – offering direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies.</p> <p>By focusing on true disease biology rather than population-based risk estimates, this approach is designed to help physicians prioritize and personalize treatment for each individual patient.</p> <p>For more information, visit <a href="http://elucid.com">elucid.com</a>.</p> <p aria-hidden="true"> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/elucid-announces-commercial-availability-lesion-inspection-tool-plaque-iq" data-a2a-title="Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Felucid-announces-commercial-availability-lesion-inspection-tool-plaque-iq&title=Elucid%20Announces%20Commercial%20Availability%20of%20Lesion%20Inspection%20Tool%20for%20Plaque-IQ"></a></span> </article> <article> <h1>AliveCor Launches Handheld 12-Lead ECG with Single-Cable Design</h1> <p>tim.hodson — Wed, 15 Apr 2026 16:36:47 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Photo: AliveCor</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Wed, 04/15/2026 - 11:36</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 15, 2026 – AliveCor has received CE Mark (Conformité Européenne) for the Kardia 12L electrocardiogram (ECG) System powered by KAI 12L AI technology. Kardia 12L is an AI-powered, portable 12-lead ECG system featuring a unique, single-cable design for health care professionals (HCPs). Powered by KAI 12L, the system enables faster, easier detection of 35 cardiac determinations, including acute myocardial infarction (MI) and the most common types of cardiac ischemia.</p> <p>“Securing CE Mark for the Kardia 12L is a defining moment in our strategy to scale AliveCor’s global footprint,” said Simona Esposito, Senior Vice President of Sales, Global Markets at AliveCor. “Our priority is to get this life-saving technology into the hands of as many clinicians as possible, especially in settings where traditional, bulky ECG carts simply aren't practical. By simplifying the hardware without sacrificing diagnostic depth, we are fundamentally improving access to high-quality cardiac care and reducing the burden of cardiovascular disease in the EU.” </p> <p aria-hidden="true"><b>Technical Specifications/Capabilities </b></p> <p>Kardia 12L is a portable, AI-guided, 12-lead ECG solution whose measurements and ECG interpretation <a href="https://www.heartrhythmjournal.com/article/S1547-5271(24)00797-5/fulltext">are similar to standard 12-lead ECG solutions,</a> right at the point of care, enabling rapid acquisition of complete ECG information and offering a better patient experience.</p> <ul type="disc"><li><b>35 Cardiac Determinations: </b>KAI 12L detects life-threatening cardiac conditions using a reduced leadset and can<b> </b>identify a comprehensive range of conditions. This includes 14 arrhythmias and 21 morphologies including serious conditions like acute MI and the most common types of cardiac ischemia.</li> <li><b>Rapid Detection: </b>Specifically designed to expand access to accurate cardiac data across diverse healthcare and acute settings, the system allows for the rapid identification of life-threatening conditions like heart attack. </li> <li><b>Operational Efficiency:</b> The device weighs 0.13 kg (0.3 lbs) and is battery-operated, allowing it to be used by HCPs in primary care, urgent care, pharmacy, the home and rural clinics where traditional ECG machines may be impractical due to their size and complexity. </li> <li><b>Improved Patient and Clinician Experience: </b>The simplified five-electrode setup makes it less invasive for patients, who do not need to fully disrobe during a reading, and typically allows for faster acquisition. <a href="https://www.heartrhythmopen.com/article/S2666-5018(25)00187-4/fulltext">Research has shown</a> nearly a 30% reduction in ECG acquisition time compared to standard 12-lead setups.</li> </ul><p>“In a fast-paced clinical environment, every second counts, but we cannot sacrifice accuracy for speed,” said Dr. Alejandro Barbagelata, Adjunct Assistant Professor of Medicine and Cardiology at Duke University. “Kardia 12L offers a unique combination of portability and diagnostic depth, allowing HCPs to make informed care decisions. By streamlining the acquisition process, it enables clinicians to identify life-threatening conditions like MI much faster, leading to better patient outcomes across the board.”</p> <p>Since its FDA clearance and subsequent launch in the United States in June 2024, Kardia 12L has seen growing global adoption including in India, Australia, New Zealand, Vietnam and Canada. The system has been adopted by clinicians across the globe capturing critical heart data on tens of thousands of patients. Most notably, the system has identified over 4,000 instances of MI and ischemia, facilitating life-saving care for those who need it most.</p> <p>This launch comes at a pivotal time, as the European Union reinforces its commitment to tackling cardiovascular diseases–the leading cause of mortality in Europe–through its EU Cardiovascular Health Plan, which prioritizes early detection, prevention, and improved access to care.</p> <p>Kardia 12L will be first available for healthcare providers in France, Germany, Italy, Spain, and the United Kingdom, and will be followed by additional European countries soon.</p> <p>For more information, please visit: <a href="https://alivecor.com/uk/products/kardia12l">https://alivecor.com/uk/products/kardia12l</a>. </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/alivecor-launches-handheld-12-lead-ecg-single-cable-design" data-a2a-title="AliveCor Launches Handheld 12-Lead ECG with Single-Cable Design"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Falivecor-launches-handheld-12-lead-ecg-single-cable-design&title=AliveCor%20Launches%20Handheld%2012-Lead%20ECG%20with%C2%A0%20Single-Cable%20Design"></a></span> </article> <article> <h1>EU NextGen Project Advances Personalized Cardiology</h1> <p>tim.hodson — Tue, 14 Apr 2026 21:54:57 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Tue, 04/14/2026 - 16:54</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 10, 2026 — As artificial intelligence (AI) capabilities increase, one of the issues that is hindering progress is the ability of AI to integrate multiple data types from various sources (multimodal data) to develop personalized interventions. For example, how to combine highly detailed genomic data with cardiology imaging and other data (text, audio, sensor data) from multiple sources into a secure "digital fabric" — a unified system to improve analytical accuracy, robustness, and depth that can be used to train the next generation of AI models.</p> <p>The European Union’s NextGen project is developing tools to remove barriers in multimodal data integration, which is complex due to privacy and governance requirements, the presence of multiple standards, distinct data formats, and underlying data complexity and volume. The project has been designed for interventions specifically for cardiology.</p> <p>NextGen tools will ensure health data remains meaningful and "readable" across different borders and hospital systems without losing its original clinical context, and allows researchers to discover relevant cardiovascular datasets without moving or exposing sensitive patient information. Especially relevant is the ability of NextGen to integrate genomic data, which is both personal to the patient and highly complex. Recently, the price of genomic sequencing has fallen substantially, meaning it can be used in the development of medical interventions with the help of AI. The tools created will also ‘shift power’ to the participants, by hard-coding the appropriate ethical constraints and governance into how the data interacts within the network.</p> <p>The NextGen tools developed are aligned with ongoing initiatives, including “1+ Million Genomes” — a project aiming to enable secure access to genomic and corresponding clinical data across Europe, supporting research, health policy and personalized healthcare.</p> <p>This work also directly supports the European Health Data Space (EHDS) framework. EHDS aims to create a secure, unified system for health data exchange across the EU, fostering innovation, improving healthcare delivery, and strengthening Europe’s global leadership in digital health.</p> <p>Several real-world pilots will demonstrate the effectiveness of the NextGen tools and will be integrated into the NextGen Pathfinder network of five collaborating clinical sites as a self-contained data ecosystem and comprehensive proof of concept.</p> <p>Prof. Steffen Petersen, Queen Mary University of London, and ESC volunteer said, “Clinicians rely on a wide range of clinical information to diagnose disease, predict risk, guide treatment and monitor outcomes. However, health data science has not yet fully captured the power of multimodal data such as symptoms, signs, electrocardiograms, blood tests, and imaging. Bringing these data together is crucial for advancing data-enabled innovation in healthcare, and NextGen represents a major step forward.”</p> <p>Find out more information about NextGen at <a href="http://www.nextgentools.eu">www.nextgentools.eu</a></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/eu-nextgen-project-advances-personalized-cardiology" data-a2a-title="EU NextGen Project Advances Personalized Cardiology"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Feu-nextgen-project-advances-personalized-cardiology&title=EU%20NextGen%20Project%20Advances%20Personalized%20Cardiology"></a></span> </article> <article> <h1>New Study Uncovers Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors</h1> <p>tim.hodson — Tue, 14 Apr 2026 19:05:57 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Tue, 04/14/2026 - 14:05</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p align="left">April 14, 2026 — <a href="https://implicity.com/">Implicity</a>, a provider of remote patient monitoring and cardiac data management solutions, recently presented new research at the 2026 European Heart Rhythm Association Congress (EHRA) examining why false-positive alerts remain a persistent challenge in implantable cardiac monitors (ICMs) — even in devices equipped with manufacturer AI algorithms. While physicians experience this burden every day, the findings provide new insight into why it persists, identifying guideline-based interpretation gaps and signal-detection issues as key drivers of non-actionable alerts across modern ICM platforms.</p> <p align="left">In a cross-manufacturer analysis of 2,659 rhythm episodes from 1,710 patients implanted with ICMs from Medtronic, Biotronik, Abbott and Boston Scientific, findings revealed that even in AI-equipped devices, 32.9% of episodes were still non-actionable, with another 30.6% deemed indeterminate. Among devices without proprietary AI algorithms, 45.4% of episodes were non-actionable and 20.1% indeterminate.</p> <p align="left">To conduct the analysis, an independent expert adjudication committee applied a standardized annotation framework aligned with international electrophysiology guidelines to determine whether device-detected episodes met the diagnostic criteria for clinically meaningful arrhythmias.</p> <p align="left">The findings provide new insight into why false-positive alerts persist even as device algorithms have evolved. Investigators found that many alerts stem from how device algorithms interpret rhythm signals relative to guideline-defined arrhythmia criteria. When those interpretations diverge from clinical definitions, benign rhythms or signal artifacts, such as premature ventricular contractions or electrical noise, may be labeled as clinically significant events.</p> <p>The analysis also identified specific signal-detection mechanisms contributing to these alerts. Episodes labeled as cardiac “pause” events emerged as a major driver, with 46.8% ultimately determined to be false positives caused by R-wave undersensing, where the device fails to detect a heartbeat and incorrectly interprets the signal as a pause.</p> <p>“False-positive alerts remain one of the biggest operational challenges in remote cardiac monitoring,” said Niraj Varma, MD, PhD, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic. “Every episode flagged by an implantable cardiac monitor must be reviewed by a clinician, yet even devices equipped with manufacturer AI algorithms still generate a substantial number of non-actionable alerts. When interpretation varies across device platforms and guideline definitions are not consistently applied, it becomes more difficult for physicians to quickly determine which events truly require clinical attention.”</p> <p>Building on these findings, investigators conducted a second analysis, also presented at EHRA, to examine whether an additional AI layer could help address these persistent false-positive alerts. The study evaluated the Implicity ILR ECG Analyzer*, a cloud-based algorithm designed to analyze ICM transmissions across multiple manufacturer platforms using a standardized guideline-based framework.</p> <p>The results showed that Implicity’s cloud-based AI algorithm maintained very high sensitivity for detecting clinically meaningful arrhythmias — 98.3% in AI-equipped devices and 94.3% in non-AI models—while filtering a substantial proportion of non-actionable alerts. Specificity reached 61.6% and 75.6% respectively, with a consistent positive predictive value of approximately 74% across both groups, demonstrating reliable diagnostic performance across different generations of implantable cardiac monitors.</p> <p>“Remote monitoring only works if clinicians can trust the alerts they receive,” said Arnaud Rosier, MD, PhD, electrophysiologist, CEO, and co-founder of Implicity. “When a large share of those alerts are non-actionable, the burden is not just operational—it diverts valuable clinical time from patients who may truly need attention. Our data shows that adding a standardized, guideline-based AI layer can reduce that noise while maintaining the high sensitivity needed to detect clinically meaningful arrhythmias.”</p> <p>The research presented at EHRA is part of Implicity’s broader clinical program focused on improving the accuracy and efficiency of remote cardiac monitoring. </p> <p> </p> <p><em>* The version of ILR ECG Analyzer evaluated in this study (V2) is not yet FDA cleared. Results may not be directly applicable to the currently cleared version</em></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/new-study-uncovers-why-false-positives-persist-ai-equipped-implantable-cardiac-monitors" data-a2a-title="New Study Uncovers Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fnew-study-uncovers-why-false-positives-persist-ai-equipped-implantable-cardiac-monitors&title=New%20Study%20Uncovers%20Why%20False%20Positives%20Persist%20in%20AI-Equipped%20Implantable%20Cardiac%20Monitors"></a></span> </article> <article> <h1>Studies Show Heart Failure is Common in Patients with Afib Detected During Screening</h1> <p>tim.hodson — Tue, 14 Apr 2026 15:53:40 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Photo: Getty Images</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Tue, 04/14/2026 - 10:53</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 13, 2026 — Heart failure is common in people who have atrial fibrillation detected during screening, according to a presentation at<strong> </strong><a href="https://www.escardio.org/events/congresses/ehra-congress/?utm_medium=Email&utm_source=&utm_campaign=esc-press-ehra-strokestop-13apr2026">EHRA 2026,<sup>1</sup></a> the annual congress of the <a href="https://www.escardio.org/communities/associations/ehra/?utm_medium=Email&utm_source=&utm_campaign=esc-press-ehra-strokestop-13apr2026">European Heart Rhythm Association</a>, a branch of the <a href="https://www.escardio.org/?utm_medium=Email&utm_source=&utm_campaign=esc-press-ehra-strokestop-13apr2026">European Society of Cardiology </a>. </p> <p>Atrial fibrillation (AF) affects almost 38 million people worldwide, with the prevalence predicted to double over the next 35 years.<sup>2</sup> Stroke is a feared outcome of AF, but heart failure (HF) also occurs frequently in patients with AF and is a major cause of death.<sup>3</sup></p> <p>“HF and AF have a bidirectional relationship and accelerate each other’s progression, so it is important to identify and treat HF early in patients with AF,” explained Doctor Gina Sado from Danderyd Hospital, Stockholm, Sweden. “HF has been well studied in patients with clinically known AF, but little is known about the incidence and timing of HF in individuals whose AF has been detected during screening.”</p> <p>In the Swedish STROKESTOP and STROKESTOP II studies,<sup>4,5</sup> individuals aged 75–76 years were randomized to receive ECG-based AF screening or to serve as controls. This post-hoc analysis studied the incidence of new HF diagnosis based on a median follow-up of 6.9 years for STROKESTOP and 5.1 years for STROKESTOP II. Data on HF diagnoses and mortality were obtained from national registries. Cox regression was used to estimate the hazard ratios (HRs) for incident HF across groups.</p> <p>Out of 6,824 individuals screened in STROKESTOP, new AF was detected in 252 individuals and of these, 57 were diagnosed with HF (23%) over the follow-up period.</p> <p>Out of 6,601 individuals screened in STROKESTOP II, new AF was detected in 152 individuals and of these, 31 were diagnosed with HF (20%) over the follow-up period.</p> <p>In STROKESTOP, screening-detected AF was associated with a threefold increased risk of HF compared with individuals without AF (adjusted HR 3.19; 95% confidence intervals [CI] 2.42 to 4.21) and with a comparable HF risk to patients with previously known AF (adjusted HR 2.86; 95% CI 2.34 to 3.50). Similar results were observed in STROKESTOP II.</p> <p>Notably, HF was diagnosed early, within 6 months after AF detection in both studies and AF groups.</p> <p>Summing up the results, Doctor Sado concluded: “In individuals with screening-detected AF, the risk of developing HF was threefold that of participants without AF and comparable to that of patients with clinically known AF. These findings suggest that asymptomatic AF is not a benign condition and highlight the need for early detection of both AF and HF.”</p> <p><u>Funding</u> <br /><em>STROKESTOP was supported by Stockholm County Council, the Swedish Heart & Lung Foundation, King Gustav V and Queen Victoria's Freemasons' Foundation, the Klebergska Foundation, the Tornspiran Foundation, the Scientific Council of Halland Region, the Southern Regional Healthcare Committee, the Swedish Stroke Fund, Carl Bennet AB, CIMED, Boehringer Ingelheim, Bayer, Bristol Myers Squibb and Pfizer. </em></p> <p>STROKESTOP II was supported by Roche Diagnostics, Carl Bennet AB, CIMED, Stockholm Region and the Swedish Heart Lung Foundation. </p> <p> <b>References:   </b></p> <ol><li>‘Heart failure over time in patients with screening detected atrial fibrillation - a posthoc analysis of the STROKESTOP and STROKESTOP II studies’ presented during the Atrial fibrillation miscellaneous session on 13 April at 08:30 to 09:30 in Room Agora. </li> <li>Lane DA, Andrade JG, Arbelo E, et al. Atrial fibrillation. Lancet. 2026;407:1000−1013. </li> <li>[Deisenhofer I. Atrial fibrillation in heart failure: Prime time for ablation! Heart Rhythm O2. 2021;2(6Part B):754−761. </li> <li>Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicenter, parallel group, unmasked, randomized controlled trial. Lancet. 2021;398:1498−1506. </li> <li>Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace 2020;22:24–32. </li> </ol></div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/studies-show-heart-failure-common-patients-afib-detected-during-screening" data-a2a-title="Studies Show Heart Failure is Common in Patients with Afib Detected During Screening"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fstudies-show-heart-failure-common-patients-afib-detected-during-screening&title=Studies%20Show%20Heart%20Failure%20is%20Common%20in%20Patients%20with%20Afib%20Detected%20During%20Screening"></a></span> </article> <article> <h1>Researchers Develop Machine Learning Model to Predict How CPAP Affects CVD Risk in Obstructive Sleep Apnea Patients</h1> <p>tim.hodson — Tue, 14 Apr 2026 15:09:37 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Image: Getty Images</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Tue, 04/14/2026 - 10:09</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>April 9, 2026 — <a href="https://www.mountsinai.org/">Mount Sinai </a>researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in patients with obstructive sleep apnea, according to findings recently published in <a href="https://www.nature.com/articles/s43856-026-01457-1"><em>Communications Medicine</em>.</a></p> <p>The team said their study is the first to provide estimates of whether continuous positive airway pressure (CPAP), a widely used therapy for obstructive sleep apnea, will increase or decrease an individual’s cardiovascular risk. It highlights the potential for precision medicine and varied approaches to tailor clinical care and reduce cardiovascular disease risk in vulnerable patients.</p> <p>Obstructive sleep apnea is a common, serious condition in which breathing repeatedly stops and starts during sleep. It affects an estimated 25 million people in the United States, and is associated with elevated risks for cardiovascular disease, including stroke and heart disease. CPAP, which provides a continuous stream of pressurized air through a mask and helps eliminate breathing disturbances during sleep, remains the most effective treatment for sleep apnea. However, prior large studies have not shown that CPAP lowers risks for cardiovascular disease in patients with this disease.</p> <p>The Mount Sinai researchers used a machine learning algorithm to create an analysis model that predicts how CPAP could affect an individual’s cardiovascular health — estimating each patient’s likeliness of benefit or harm from the therapy, based on their sleep and health information.</p> <p>“Our findings represent a significant advancement in personalized medicine, moving away from a one-size-fits-all strategy in the treatment of obstructive sleep apnea,” said co-corresponding author Neomi A. Shah, MD, MPH, MSC, Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), and Artificial Intelligence and Human Health, and Associate Chief for Academic Affairs in the Division of Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai. “This underscores the value of new data-driven approaches like our model to assist clinicians in making informed decisions about CPAP treatment recommendations, enhancing personalized care to meet the individual needs of every patient.”</p> <p>The Mount Sinai team analyzed data from the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, the largest clinical cohort evaluating CPAP for cardiovascular disease prevention with more than 2,600 participants from 89 sites in seven countries, to estimate individualized treatment effect scores. They considered more than 100 predictors from sleep and health information to establish 23 key baseline features, such as prior medical conditions and smoking status, in their analysis model.</p> <p>The researchers found that treatment response significantly varied across the cohort. The model identified a subgroup who were expected to have improved cardiovascular risk with CPAP treatment; participants in this subgroup who were randomly assigned to receive the therapy experienced a 100-fold improvement in future cardiac risk compared with usual care. Conversely, those in a subgroup predicted to be harmed by the therapy experienced a greater than 100-fold increase in cardiovascular disease outcomes, including recurrent strokes and heart attacks, when receiving CPAP compared with usual care.</p> <p>“These results demonstrate the power of machine learning for prediction of treatment effects in an era of precision medicine; however, such models require careful validation to prove their utility in clinical practice,” said co-primary author Oren Cohen, MD, Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) at the Icahn School of Medicine.</p> <p>“Artificial intelligence in medicine must move beyond pattern recognition to causal reasoning,” said co-corresponding author Mayte Suarez-Farinas, PhD, Co-Director for the Division of Biostatistics and Data Science, and Professor of Population Health Science and Policy, and Artificial Intelligence and Human Health, at the Icahn School of Medicine. “By estimating individualized treatment effects over time using randomized clinical trial data, we move predictive AI toward decision-support tools grounded in causality and capable of informing real-world treatment decisions and improving outcomes.”</p> <p>Investigators from the SAVE trial contributed to this study, including those at The George Institute for Global Health in Sydney, Australia; University of New South Wales, Sydney; School of Electrical and Mechanical Engineering at the University of Adelaide in Adelaide, Australia; and Adelaide Institute for Sleep Health/Flinders Health and Medical Research Institute Sleep Health at Flinders University in Adelaide.</p> <p><em>The study was supported by funding from the Stony-Wold Herbert Fund (Fellowship Award), American Academy of Sleep Medicine Foundation (AASMF Physician Scientist Training Award and 250-SR-21), and the National Heart, Lung, and Blood Institute at the National Institutes of Health (T32HL160511-02 and R01HL143221).</em></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/researchers-develop-machine-learning-model-predict-how-cpap-affects-cvd-risk-obstructive" data-a2a-title="Researchers Develop Machine Learning Model to Predict How CPAP Affects CVD Risk in Obstructive Sleep Apnea Patients"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fresearchers-develop-machine-learning-model-predict-how-cpap-affects-cvd-risk-obstructive&title=Researchers%20Develop%20Machine%20Learning%20Model%20to%20Predict%20How%20CPAP%20Affects%20CVD%20Risk%20in%20Obstructive%20Sleep%20Apnea%20Patients"></a></span> </article> </main></body></html>